Description
TRUMAB 150 MG is a targeted biological therapy containing Trastuzumab, a monoclonal antibody specifically engineered to treat HER2-positive cancers. Manufactured by Glenmark Pharmaceuticals, it is a trusted biosimilar used in the treatment of HER2-positive breast cancer and metastatic gastric (stomach) cancer. Trumab works by binding to the Human Epidermal Growth Factor Receptor 2 (HER2) proteins found on the surface of specific cancer cells. By blocking these receptors, it inhibits the growth signals that cause tumors to spread and alerts the body’s immune system to target and destroy the malignant cells. The 150 mg vial provides flexible dosing options for individualized clinical protocols.
